Intranasally administered peptidic viral fusion inhibitor protected hDPP4 transgenic mice from MERS-CoV infection

BACKGROUND: Middle East respiratory syndrome coronavirus (MERS-CoV), a new coronavirus that emerged in 2012, causes severe and fatal acute respiratory illness in man. Its high mortality (roughly 38%) has raised public fear worldwide, calling for the development of effective and safe therapeutics to...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Shibo, Tao, Xinrong, Xia, Shuai, Garron, Tania, Yu, Fei, Du, Lanying, Lu, Lu, Tseng, Chien-Te K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159274/
http://dx.doi.org/10.1016/S0140-6736(15)00625-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159274/
http://dx.doi.org/10.1016/S0140-6736(15)00625-X

Ejemplares similares